Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A comprehensive review of available omics data resources and molecular profiling for precision glioma studies.

Zhao Z, Zhang K, Wang Z, Wang K, Liu X, Wu F, Chen J.

Biomed Rep. 2019 Jan;10(1):3-9. doi: 10.3892/br.2018.1168. Epub 2018 Nov 14. Review.

2.

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.

Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G.

Acta Neuropathol. 2015 May;129(5):679-93. doi: 10.1007/s00401-015-1409-0. Epub 2015 Mar 18.

3.

[Classification of gliomas. Current progress and perspectives].

Capper D, Reifenberger G.

Nervenarzt. 2015 Jun;86(6):672, 674-6, 678-80, passim. doi: 10.1007/s00115-014-4223-3. German.

PMID:
25989737
4.

DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.

Paul Y, Mondal B, Patil V, Somasundaram K.

Clin Epigenetics. 2017 Apr 4;9:32. doi: 10.1186/s13148-017-0331-9. eCollection 2017.

6.

Treatment of anaplastic glioma.

Wick W, Wiestler B, Platten M.

Cancer Treat Res. 2015;163:89-101. doi: 10.1007/978-3-319-12048-5_6. Review.

PMID:
25468227
7.

Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.

Cimino PJ, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel B, von Deimling A, Jones D, Reifenberger G, Weller M, Holland EC.

Acta Neuropathol Commun. 2017 May 22;5(1):39. doi: 10.1186/s40478-017-0443-7.

8.

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G.

Neuro Oncol. 2012 Sep;14 Suppl 4:iv100-8. doi: 10.1093/neuonc/nos206. Review.

9.

Molecular neuropathology of gliomas.

Riemenschneider MJ, Reifenberger G.

Int J Mol Sci. 2009 Jan;10(1):184-212. doi: 10.3390/ijms10010184. Epub 2009 Jan 7. Review.

10.

Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel.

Zacher A, Kaulich K, Stepanow S, Wolter M, Köhrer K, Felsberg J, Malzkorn B, Reifenberger G.

Brain Pathol. 2017 Mar;27(2):146-159. doi: 10.1111/bpa.12367. Epub 2016 Apr 19.

PMID:
26919320
11.

Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification.

Vigneswaran K, Neill S, Hadjipanayis CG.

Ann Transl Med. 2015 May;3(7):95. doi: 10.3978/j.issn.2305-5839.2015.03.57. Review.

12.

Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.

Ballester LY, Huse JT, Tang G, Fuller GN.

Hum Pathol. 2017 Nov;69:15-22. doi: 10.1016/j.humpath.2017.05.005. Epub 2017 May 23.

PMID:
28549927
13.

Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.

Marko NF, Prayson RA, Barnett GH, Weil RJ.

Genomics. 2010 Jan;95(1):16-24. doi: 10.1016/j.ygeno.2009.09.007. Epub 2009 Oct 14.

14.

Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.

Delfanti RL, Piccioni DE, Handwerker J, Bahrami N, Krishnan A, Karunamuni R, Hattangadi-Gluth JA, Seibert TM, Srikant A, Jones KA, Snyder VS, Dale AM, White NS, McDonald CR, Farid N.

J Neurooncol. 2017 Dec;135(3):601-609. doi: 10.1007/s11060-017-2613-7. Epub 2017 Sep 4. Erratum in: J Neurooncol. 2017 Sep 13;:.

15.

Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.

Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Luks T, Wiencke JK, Jenkins RB, Wrensch MR.

Acta Neuropathol. 2017 Jun;133(6):1001-1016. doi: 10.1007/s00401-017-1690-1. Epub 2017 Mar 2.

16.

Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status.

Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, Neumaier B, Shah NJ, Langen KJ, Galldiks N.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):443-451. doi: 10.1007/s00259-017-3846-6. Epub 2017 Oct 17.

PMID:
29043400
17.

Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.

Akyerli CB, Yüksel Ş, Can Ö, Erson-Omay EZ, Oktay Y, Coşgun E, Ülgen E, Erdemgil Y, Sav A, von Deimling A, Günel M, Yakıcıer MC, Pamir MN, Özduman K.

J Neurosurg. 2018 Apr;128(4):1102-1114. doi: 10.3171/2016.11.JNS16973. Epub 2017 Jun 16.

PMID:
28621624
18.

[OMICS and biomarkers of glial tumors].

Idbaih A.

Rev Neurol (Paris). 2011 Oct;167(10):691-8. doi: 10.1016/j.neurol.2011.07.007. Epub 2011 Sep 1. Review. French.

PMID:
21889780
19.

Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.

Miller JJ, Shih HA, Andronesi OC, Cahill DP.

Cancer. 2017 Dec 1;123(23):4535-4546. doi: 10.1002/cncr.31039. Epub 2017 Oct 5. Review.

20.

Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.

Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T, Tominaga T.

J Neurooncol. 2016 Sep;129(3):505-514. doi: 10.1007/s11060-016-2201-2. Epub 2016 Jul 11.

PMID:
27401154

Supplemental Content

Support Center